fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Nintedanib

All products: not a benefit

Jamp Nintedanib · DIN 02550849 · 100 mg · capsule

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 17, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot paid by ODB 65 and over without Exceptional Access approval; this DIN is on the ministry's EAP drug list: submit an EAP request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Ofev; DOSAGE FORM/ STRENGTH: 100 mg,150 mg capsules — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Nintedanib Brand(s): Ofev DOSAGE FORM/ STRENGTH: 100 mg,150 mg capsules Updated: April 29, 2022 Initial approval criteria: For the treatment of adult patients with a diagnosis of mild to moderate idiopathic pulmonary fibrosis (IPF): • Diagnosis confirmed by a respirologist and a high-resolution CT scan. • All other causes of restrictive lung disease (e.g. collagen vascular disorder or hypersensitivity pneumonitis) should be excluded. • Mild to moderate IPF is defined as forced vital capacity (FVC) greater than or equal to 50% of predicted. • Patient is under the care of a physician with experience in IPF. Initial approval period: 7 months (allow 4 weeks for repeat pulmonary function tests) Initial renewal criteria (at 6 months): Patients must NOT demonstrate progression of disease defined as an absolute decline in percent predicted FVC of ≥10% from initiation of therapy until renewal (initial 6 month treatment period). If a patient has experienced progression as defined above, then the results should be validated with a confirmatory pulmonary function test conducted 4 weeks later. Initial Renewal Duration: 6 Months Second and subsequent renewals (at 12 months and thereafter): Patients must NOT demonstrate progression of disease defined as an absolute decline in percent predicted FVC of ≥10% within any 12 month period. If a patient has experienced progression as defined above, then the results should be validated with a confirmatory pulmonary function test conducted 4 weeks later. Approval period: 12 months Documentation/information required: • If high-resolution CT scan is not available, lung biopsy may be provided to support the diagnosis of IPF as applicable and available • Full pulmonary function test results. Second Renewal Duration: 12 Months Exclusion Criteria: Combination use of Ofev (nintedanib) and Esbriet (pirfenidone) will not be funded. 435 Nintedanib Brand(s): Ofev DOSAGE FORM/ STRENGTH: 100 mg, 150 mg capsules Initiation Criteria For the treatment of chronic fibrosing interstitial lung disease with a progressive phenotype (PF-ILD) in patients meeting all of the following criteria: • Has a confirmed diagnosis by a specialist in interstitial lung diseases. Provide a copy of the consultation note. • Has a forced vital capacity (FVC) greater than or equal to 45% of predicted. • Requests must come from or in consultation with a specialist with experience in managing interstitial lung diseases. Initial requests should contain the following information: • Pulmonary function test results. • A high-resolution computed tomography (HRCT) scan, if available. • A consultation note from a specialist in interstitial lung diseases. Exclusion Criteria: • Nintedanib will not be funded as combination therapy with pirfenidone. Renewal Criteria: Renewals will be considered in patients who have not experienced an absolute decline in percent predicted forced vital capacity of greater than or equal to 10% over the preceding year of treatment with nintedanib. Duration of approval of initials and renewal: 12 months Approved Dosage: up to 150 mg orally every 12 hours 436 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 435, record 266, corpus 2025-01-01; name match only, not an eligibility decision
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Nintedanib · DIN 02550849 Manufacturer: Jamp Pharma Corporation; listing date 2026-01-30 Health Canada: Marketed since 2025-12-22 · brand JAMP NINTEDANIB · ATC L01EX09 NINTEDANIB · form Capsule · route Oral · ingredients NINTEDANIB (NINTEDANIB ESILATE) 100 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp Nintedanib: Formulary list price $14.21 per unit (the source does not state the unit; exact figure $14.2084). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02550849)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02550849). DIN 02550849: Jamp Nintedanib Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 480200001; group id 569; item number 1519; lccId None; manufacturer id JPC Source form: Cap; strength: 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $14.2084; ministry $14.2084 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02550849 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103962
Interchangeable products
Auro-Nintedanib · DIN 02526891 · $14.2084 Ofev · DIN 02443066 · $14.2084
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (48:00 COUGH PREPARATIONS) and how they are covered

Matched class: 48:00 COUGH PREPARATIONS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Some products covered without a code (check the product listing): DEXTROMETHORPHAN HBR, HYDROCODONE BITARTRATE 48:00 COUGH PREPARATIONS

PIRFENIDONE

· 12 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 267mg, 801mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 48:00 48:04 Antitussives

DEXTROMETHORPHAN HBR

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 3mg/mL · O/L

HYDROCODONE BITARTRATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 1mg/mL · O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 48:04 48:08 Expectorants

GUAIFENESIN

· 3 products · Listed, not a benefit · strengths: 20mg/mL · O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 48:08
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: pulmonary fibrosis
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. PIRFENIDONE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS ESBRIET® (pirfenidone) is indicated for treatment of idiopathic pulmonary fibrosis (IPF) in adults. 1.1. PM: https://pdf.hres.ca/dpd_pm/00073373.PDF; date November 9, 2023; DIN 02464489; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1 INDICATIONS OFEV (nintedanib) capsules are indicated for: • The treatment of Idiopathic Pulmonary Fibrosis (IPF) • To slow the rate of decline in pulmonary function in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) • The treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (also known as progressive fibrosing ILD) (see 14 CLINICAL TRIALS) 1.1 Pediatrics • Pediatrics (< 18 years of age): The safety and efficacy of OFEV in pediatric patients have not been studied in clinical trials and therefore, OFEV should not be used in patients under 18 years of age. 1.2 Geriatrics • Geriatrics (> 65 years of age): No dose adjustment is necessary in patients 65 years and older. https://pdf.hres.ca/dpd_pm/00077134.PDF PM date: JUN 25, 2015 Source product: OFEV; DIN 02443066; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Prepare an Exceptional Access request

SADIE has its own form for many drugs; this checklist prepares the answers; the ministry decides. Open SADIE

Use this text in SADIE’s free-text fields or read from it on a Telephone Request Service call. Review marks do not indicate eligibility. Evidence stays in this page until you copy it; nothing entered here is sent or saved. Do not enter patient identifiers.

EAP Telephone Request Service: The TRS can be accessed by calling toll-free at 1-866-811-9893 or 416-327-8109 (Toronto area) between 8:30 a.m. and 5:00 p.m. Monday through Friday (except holidays) and selecting the TRS option. Source; updated September 15, 2026

EAP fax: In Ontario: 1-866-811-9908 or 416-327-7526 (Toronto area). Outside Ontario: 1-833-905-4260. Source; updated September 15, 2026

Posted turnaround and Telephone Request Service scope
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 28, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days |
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
Source; updated October 05, 2026

Nintedanib (Ofev)

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Prepare answers: For the treatment of adult patients with a diagnosis of mild to moderate idiopathic pulmonary fibrosis (IPF):

Ministry criteria corpus 2025-01-01; page 435

Nintedanib Brand(s): Ofev DOSAGE FORM/ STRENGTH: 100 mg,150 mg capsules Updated: April 29, 2022
Initial approval criteria:
For the treatment of adult patients with a diagnosis of mild to moderate idiopathic pulmonary fibrosis (IPF):
• Diagnosis confirmed by a respirologist and a high-resolution CT scan.
• All other causes of restrictive lung disease (e.g. collagen vascular disorder or hypersensitivity pneumonitis) should be excluded.
• Mild to moderate IPF is defined as forced vital capacity (FVC) greater than or equal to 50% of predicted.
• Patient is under the care of a physician with experience in IPF.
Initial approval period: 7 months (allow 4 weeks for repeat pulmonary function tests)
Initial renewal criteria (at 6 months):
Patients must NOT demonstrate progression of disease defined as an absolute decline in percent predicted FVC of ≥10% from initiation of therapy until renewal (initial 6 month treatment period). If a patient has experienced progression as defined above, then the results should be validated with a confirmatory pulmonary function test conducted 4 weeks later.
Initial Renewal Duration: 6 Months
Second and subsequent renewals (at 12 months and thereafter):
Patients must NOT demonstrate progression of disease defined as an absolute decline in percent predicted FVC of ≥10% within any 12 month period. If a patient has experienced progression as defined above, then the results should be validated with a confirmatory pulmonary function test conducted 4 weeks later.
Approval period: 12 months
Documentation/information required:
• If high-resolution CT scan is not available, lung biopsy may be provided to support the diagnosis of IPF as applicable and available
• Full pulmonary function test results.
Second Renewal Duration: 12 Months
Exclusion Criteria: Combination use of Ofev (nintedanib) and Esbriet (pirfenidone) will not be funded.
435 Nintedanib Brand(s): Ofev DOSAGE FORM/ STRENGTH: 100 mg, 150 mg capsules
Initiation Criteria
For the treatment of chronic fibrosing interstitial lung disease with a progressive phenotype (PF-ILD) in patients meeting all of the following criteria:
• Has a confirmed diagnosis by a specialist in interstitial lung diseases. Provide a copy of the consultation note.
• Has a forced vital capacity (FVC) greater than or equal to 45% of predicted.
• Requests must come from or in consultation with a specialist with experience in managing interstitial lung diseases.
Initial requests should contain the following information:
• Pulmonary function test results.
• A high-resolution computed tomography (HRCT) scan, if available.
• A consultation note from a specialist in interstitial lung diseases.
Exclusion Criteria:
• Nintedanib will not be funded as combination therapy with pirfenidone.
Renewal Criteria:
Renewals will be considered in patients who have not experienced an absolute decline in percent predicted forced vital capacity of greater than or equal to 10% over the preceding year of treatment with nintedanib.
Duration of approval of initials and renewal: 12 months
Approved Dosage: up to 150 mg orally every 12 hours
436

Prepared from the ministry's published criteria; eligibility is decided by the Exceptional Access Program.

Other review policies

For Jamp Nintedanib: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026